Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection
- 22 April 2022
- journal article
- Published by Heighten Science Publications Corporation in Journal of Clinical Nephrology
- Vol. 6 (1), 036-039
- https://doi.org/10.29328/journal.jcn.1001088
Abstract
Endotheliosis, thrombotic microangiopathy and complement system over activation have been described as pathologic features of tissue damage in the setting of coronavirus disease. Interestingly, complement-mediated cell injury is also a typical feature of atypical Hemolytic Uremic Syndrome. Indeed, a growing body of literature has described a higher risk of microangiopathy recurrence, in aHUS patients who test positive for SARS-CoV-2. The correct clinical and therapeutic management patients with a history of HUS and SARS-CoV-2 infection is not well established. We report a case of SARS-CoV-2 infection in an aHUS patient who did not develop a recurrence of the disease and that was successfully treated with convalescent immune plasma therapy.Keywords
This publication has 8 references indexed in Scilit:
- Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experienceBMC Infectious Diseases, 2021
- Atypical HUS relapse triggered by COVID-19Kidney International, 2020
- Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibitionBlood, 2020
- Anti-SARS-CoV-2 hyperimmune plasma workflowTransfusion and Apheresis Science, 2020
- Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndromeClinical Kidney Journal, 2020
- The case of complement activation in COVID-19 multiorgan impactKidney International, 2020
- Thrombotic microangiopathy in a patient with COVID-19Kidney International, 2020
- CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 GlomerulopathyJournal of the American Society of Nephrology, 2020